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Abstract (256 words) 1 
Background  The diagnostic work-up of paediatric functional gastrointestinal 2 
disorders, including irritable bowel syndrome (IBS) and functional abdominal pain – not 3 
otherwise specified (FAP-NOS), and discrimination from organic conditions, like 4 
inflammatory bowel disease (IBD), commonly includes invasive tests carrying a high burden 5 
on patients. Therefore, there is an ongoing need to develop non-invasive diagnostic 6 
biomarkers for IBS and FAP-NOS. The aim of this study was to evaluate whether paediatric 7 
IBS/FAP-NOS could be discriminated from IBD and healthy controls by faecal VOCs (volatile 8 
organic compound) analysis. 9 
Methods In this multicentre case-control study, IBS/FAP-NOS patients according to the 10 
ROME IV criteria, with age and sex matching de novo IBD patients aged 4 to 17 years, were 11 
recruited from outpatient clinics of three hospitals in Amsterdam, The Netherlands. Healthy 12 
controls (HC) were children without gastrointestinal symptoms. Faecal VOCs were analysed 13 
by means of field asymmetric ion mobility spectrometry (FAIMS, Lonestar®, Owlstone, UK). 14 
Results Faecal VOCs of 15 IBS/FAP-NOS, 30 IBD (15UC, 15CD) patients and 15 HC  were 15 
analysed and compared. Differentiation between IBS/FAP-NOS and IBD was feasible with 16 
high accuracy (AUC ± 95%CI, sensitivity, specificity; PPV; NPV; P-values; 0.94 (0.88-1), 1, 0.87, 17 
0.79, 1, 0.00000002613). IBS/FAP patients could not be discriminated HC (AUC ± 95%CI, 18 
sensitivity, specificity, PPV, NPV, P-values; (0.59 (0.41-0.77), 0.6, 0.3, 0.45, 0.76, 0.1667).  19 
Conclusion Paediatric IBS/FAP-NOS could be differentiated from IBD by faecal VOC analysis 20 
with high accuracy, but not from controls. The latter finding limits the potential of faecal 21 
VOCs to serve as diagnostic biomarker for IBS/FAP-NOS. However, it could possibly serve as 22 
additional non-invasive biomarker to discriminate between IBS/FAP-NOS and IBD.  23 
  24 
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Introduction 1 
Irritable bowel syndrome (IBS) and functional abdominal pain – not otherwise specified 2 
(FAP-NOS) are gastrointestinal disorders in children. It has a worldwide prevalence of about 3 
13% and often lasts for more than five years after the diagnosis has been established (1). 4 
Since biochemical diagnostic biomarkers are yet not available, diagnosis relies on the 5 
symptom-based ROME IV criteria (2). The ROME IV criteria include that the symptoms 6 
cannot be explained by another medical condition after appropriate evaluation. 7 
Differentiation between IBS and somatic disorders like inflammatory bowel disease (IBD) can 8 
be difficult. To exclude somatic diseases, the diagnostic work-up may include colonoscopy, 9 
which carries a high burden on patients, leads to high costs and risk of complications (3, 4). 10 
Currently, faecal calprotectin (FCP) is the most commonly used non-invasive diagnostic 11 
biomarker to discriminate between IBS/FAP-NOS and IBD, which is characterized by a high 12 
sensitivity for mucosal inflammation (0.98, 95%CI 0.95-0.99), but limited specificity (0.68, 13 
95% CI 0.50-0.86) (5). Therefore, the search for an accurate, non-invasive biomarker to 14 
differentiate between IBD and functional disorders like IBS/FAP-NOS remains. 15 
 16 
Alterations of the intestinal microbiota have been described in IBS/FAP-NOS patients (6). 17 
Yet, microbiota analysis is not desirable as a non-invasive biomarker test in clinical practice, 18 
as the analysis is complex, time-consuming and expensive (7). Assessment of volatile organic 19 
compound (VOC) composition, which are considered to reflect microbiota composition and 20 
function, is an upcoming field in metabolomics (8). VOC analysis (i.e. detecting the odours 21 
than emanate from a biological sample) has shown potential to serve as a diagnostic 22 
biomarker for a broad range of gastrointestinal diseases, in particular those linked to 23 
microbial dysbiosis, e.g. Clostridium difficile infection, IBD, colorectal cancer and necrotizing 24 
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enterocolitis (8-11). There are several techniques to analyse VOCs from simple gas sensor 1 
arrays to high-end analytical istruments such as gas chromatography/mass spectrometry. A 2 
more modern technique finding favour in many fields is Field asymmetric ion mobility 3 
spectrometry (FAIMS), which measures the mobility of ions in high electric fields.  It is 4 
characterized by high reproducibility, relatively low costs  and minimal sensor drift (12). 5 
Differentiation between IBS, active IBD and healthy controls has been subject of a study on 6 
adults, showing high sensitivity (CD 94%, UC 96%, HC 90%) and specificity (CD 82%, UC 80%, 7 
HC 80%) (13).  8 
 9 
We hypothesized that paediatric IBD and IBS/FAP-NOS could be distinguished based on 10 
differences in faecal VOC composition. The aim of this study was to investigate whether 11 
faecal VOC patterns, analysed by FAIMS, could serve as biomarker to distinguish IBS/FAP 12 
from IBD and from healthy controls, in a paediatric population. 13 
  14 
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Methods 1 
Study design 2 
This case-control study was performed at the outpatient clinics of the paediatric 3 
(gastroenterology) departments of the tertiary centres VU university medical centre,  Emma 4 
Children’s Hospital, and OLVG Oost (all centres located in Amsterdam, the Netherlands).The 5 
study was performed between December 2013 and December 2016.  6 
 7 
Study participants 8 
Three subgroups were defined: 9 
1) Inflammatory bowel disease 10 
Participants aged 4 to 17 years were extracted from an existing cohort consisting of de novo 11 
treatment-naïve paediatric IBD patients (59 CD, 40 UC), included at the VU University 12 
medical centre and the Emma Children’s Hospital (AMC) between December 2013 and 13 
October 2015 for a study on diagnostic biomarkers. The selection procedure is explained in 14 
the Matching procedure section. All participants were instructed to collect a faecal sample 15 
prior to bowel cleansing and colonoscopy. The diagnosis of IBD was made according to the 16 
revised diagnostic Porto-criteria for paediatric IBD, including endoscopic, histologic and 17 
radiologic findings(14). Localisation and behaviour of disease were classified according to the 18 
Paris Classification(15). Clinical activity was determined at study inclusion based on the 19 
Physician Global Assessment (PGA-score), levels of faecal calprotectin (FCP) and C-reactive 20 
protein (CRP). Exclusion criteria were the use of anti-/probiotics or immunosuppressive 21 
therapy three months prior to inclusion, immunocompromised disease (i.e. leukaemia, 22 
human immunodeficiency virus), diagnosis of another gastrointestinal disease, proven 23 
infectious colitis in the month before presentation (determined by positive stool culture for 24 
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Salmonella spp., Shigella spp., Yersinia spp. Campylobacter spp., Clostridium spp. toxins, or 1 
parasites in stools) and a history of gastrointestinal surgery (except appendectomy).  2 
 3 
2) IBS and FAP-NOS 4 
Children aged 4 to 17 years visiting the outpatient clinic in one of the three hospitals 5 
between August and December 2016, and fulfilling the ROME IV criteria for IBS or FAP-NOS 6 
were eligible to participate(2). All subjects completed a questionnaire on abdominal 7 
symptoms, defecation pattern based on Bristol stool chart scores, medication use and 8 
medical history. Exclusion criteria were similar to the IBD subgroup.  9 
 10 
3) Healthy controls 11 
Children aged 4 to 17 years visiting elementary and high schools in the province North-12 
Holland, The Netherlands, were instructed to collect a faecal sample. Similar to the IBS/FAP-13 
NOS group, all participants completed a questionnaire containing similar items. Exclusion 14 
criteria were functional gastrointestinal disorders according to the ROME IV criteria, 15 
diagnosis with a gastrointestinal or immunocompromised disease, history of gastrointestinal 16 
surgery (except appendectomy), or the use of pro- or antibiotics three months prior to 17 
inclusion.  18 
 19 
Ethical considerations 20 
This study was approved by the Medical Ethical Review Committee (METc) of the VU 21 
University Medical Centre under file number 2015.393, and by the local medical ethical 22 
committees of other two participating centres. Written informed consent was obtained from 23 
all parents, and from the child in case of age over twelve years. 24 
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Matching procedure 1 
A total of 15 IBS/FAP-NOS patients (9 IBS, 6 FAP-NOS) were strictly matched to 15UC, 15CD 2 
and 30HC based on age and gender. For this, the following procedure was performed. First, 3 
from the 99 IBD patients (59 CD, 40 UC) of the existing cohort, all of the eligible subjects 4 
were strictly matched to IBS/FAP-NOS patients. Then, IBD patients were randomly included 5 
from the matched groups in a 1:1:1 ratio (IBS/FAP-NOS to UC to CD).  After this, 30 HC 6 
recruited for this study were matched to the IBS/FAP-NOS group in a 1:2 ratio.   7 
 8 
Sample collection 9 
Patients were instructed to collect a fresh faecal sample in a stool container (Stuhlgefäß 10 
10ml, Frickenhausen, Germany) and instructed to store the sample in the refrigerator at 11 
home directly following bowel movement. The samples were transported to the hospital by 12 
one of the researchers, using cool elements and a cool bag. Here, samples were stored at -20 13 
ºC until further handling. 14 
 15 
Sample analysis 16 
Faecal volatile organic compounds analysis was performed using FAIMS (Lonestar, Owlstone 17 
Ltd., UK), according to the protocol as described in an earlier study by Bomers et.al. (9). In 18 
short, faecal samples were thawed to room temperature ten minutes prior to VOC analysis. 19 
A mixture of 0.5g faecal sample and 3.5mL tap water was manually shaken to homogenize 20 
the sample. Compressed air (0.1MPa) was used as carrier gas to transfer the sample 21 
headspace (the air above the sample) into the FAIMS instrument. The Lonestar was set up in 22 
a pressurised configuration with a flow rate of 2L/min. The temperatures were set at 35°C 23 
for the sample holder, 70°C for the lid and 100°C for the filter region. After the procedure 24 
11 
 
the air in the Lonestar was refreshed by analysing the headspace of 3.5mL tap water(16). 1 
The dispersion field passed through 51 equal settings between 0% and 100% (in the ratio of 2 
the high electric field to low electric field). The compensation voltage was set between +6V 3 
and -6V in 512 steps for each dispersion field(9). Each faecal sample was analysed three 4 
times sequentially, producing three matrices in 540s. For the statistical analysis, only the 5 
third matrix was used as we have previously shown that this approach gives the optimum 6 
diagnostic potential(12).  7 
 8 
Statistical analysis 9 
The demographic data of each group (IBS/FAP-NOS, UC, CD and HC) was compared using the 10 
Kruskal-Wallis-H test with the addition of the Wilcoxon-rank-sum test for continuous data. 11 
The Fisher’s exact tests was performed for dichotomous data using IBM SPSS version 22.  12 
For FAIMS analysis, each sample consisted of 52224 data point in a 2D matrix. A pre-13 
processing method was first performed to each sample data by applying a 2D discrete 14 
wavelet transform. This step aims to decompose the data and extract subtle chemical signals 15 
hidden within a much larger signal. A 10 fold cross validation was then applied, where 16 
feature selection and classifier training was performed to 90% of data (training set) and class 17 
predictions produced from 10% of data (test set). A Wilcoxon rank sum test as feature 18 
selection was used to calculate p-values in training set to identify which features are 19 
optimum for disease prediction. Four classification algorithms were applied, Sparse Logistic 20 
Regression, Random Forest, Gaussian Process, and Support Vector Machine. A receiver 21 
operator characteristic curve was created to predict area under curve (AUC), sensitivity, 22 
specificity, positive predictive value (PPV), negative predictive value (NPV), and p-values. 23 
 24 
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Results 1 
Baseline characteristics 2 
Baseline characteristics and disease specifics of the study subjects are displayed in Table 1.  3 
There were no significant differences in age, sex and BMI between the IBS/FAP-NOS, IBD and 4 
HC subgroups. In addition, no differences in faecal consistency based on the Bristol Stool 5 
Chart, faecal frequency and way of delivery were found between IBS/FAP-NOS and HC.   6 
 7 
IBS/FAP-NOS versus IBD 8 
The results of the VOC analysis by FAIMS technique are shown in Table 2. For each analysis, 9 
the best performing of the four different applied classification models is shown.  A complete 10 
overview of the data generated by the four classification models is given in supplemental 11 
Table 1-4. Faecal VOCs of IBS/FAP patients differed from IBD patients (AUC ± 95%CI, 12 
sensitivity, specificity, PPV, NPV, P-values; 0.94 (0.88-1), 0.87, 0.79, 1, 0.00000002613). 13 
Corresponding Receiver Operating Characteristic (ROC)-curves are visualised in Figure 1. An 14 
overview of the complete outcome of the four performed classifiers is displayed in 15 
supplementary tables 1-2. In addition, there were significant differences between VOC 16 
profiles of IBS/FAP-NOS patients and both UC and CD subgroups (table 2, Supp table 1-4).  17 
 18 
IBS/FAP-NOS versus HC 19 
Children diagnosed with IBS/FAP could not be discriminated from HC (AUC ± 95%CI, 20 
sensitivity, specificity, PPV, NPV, P-values; (0.59 (0.41-0.77), 0.6, 0.3, 0.45, 0.76, 0.1667) 21 
(Table 2, Supp table 1-4, Figure 1). 22 
 23 
 24 
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IBD versus HC 1 
Patients with IBD could be distinguished from HC (AUC ± 95%CI, sensitivity, specificity, PPV, 2 
NVP, P-values; 0.96 (0.9-1), 0.93, 0.97, 0.97, 0.94, 0.0000000003962) (Table 2, Supp table 1-3 
4, Figure 1). Both IBD subtypes UC and CD could each be differentiated from HC (Table 2, 4 
Supp table 1-4). 5 
 6 
IBS versus FAP 7 
Patients with IBS could not be discriminated from patients with FAP-NOS (AUC ± 95%CI, 8 
sensitivity, specificity, PPV, NPV, P-values; (0.76 (0.44-1), 1, 0.6, 0.83, 1, 0.9504) (Table 2, 9 
Supp table 1-4). 10 
 11 
Duration of sample storage 12 
Duration of storage of the collected faecal samples did not differ between IBS/FAP-NOS and 13 
HC.  IBD samples were stored for a significantly longer period compared to both other 14 
subgroups (medium in months; CD 31.7; UC 45.1; IBS/FAP 0.6; HC 1.4, P<0.001).   15 
  16 
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Discussion 1 
In this multicentre case-control study, we observed that faecal VOC profiles could 2 
discriminate paediatric IBS/FAP-NOS patients from children with new onset, treatment naïve 3 
IBD with high accuracy, but not from HC. Furthermore, we validate earlier study results that 4 
IBD and HC could be discriminated with high accuracy. 5 
 6 
Studies on the potential of faecal VOC profiling to discriminate between paediatric IBS/FAP-7 
NOS and IBD have not yet been performed. Ahmed et. al. compared faecal VOC profiles of 30 8 
adult diarrhoea-predominant IBS (IBS-D) patients, with 62 active CD, 48 active UC and 109 9 
healthy subjects using gas chromatography-mass spectrometry (GC-MS)(13). In that study, 10 
IBS-D could be discriminated from IBD, based on 60 statistically significant different 11 
metabolites. These metabolites were used to construct a discriminatory model with high 12 
diagnostic accuracy (AUC IBS-D vs CD 0.97; IBS-D vs UC 0.96; p=0.001). This diagnostic 13 
accuracy is similar to that observed in our study. In addition, significantly increased levels of 14 
28 faecal metabolites were identified in IBS-D patients compared to HC and were used for a 15 
discriminatory model as well (AUC 0.92; p<0.05). In the present study, however, IBS/FAP-16 
NOS could not be discriminated from HC. This difference could possibly be explained by our 17 
relatively small sample size. Another explanation could be our heterogeneous IBS/FAP-NOS 18 
group in which subjects could experience a variety of symptoms (diarrhoea, abdominal pain, 19 
bloating, constipation), whereas Ahmed. et. al. solely included patients with diarrhoea-20 
predominant IBS type. Though, we observed no significant differences in VOC profiles 21 
between the two subgroups IBS and FAP-NOS. In addition, the diagnostic accuracy could 22 
differ due to the fact that GC-MS is a more sensitive technique compared to FAIMS(17). 23 
However, since the diagnostic accuracy to differentiate between IBD and IBS/FAP-NOS is 24 
15 
 
very similar between these studies, we believe this had minimal influence on our study 1 
outcomes.  2 
In a study performed by Walton et. al., differences in faecal VOC composition between adult 3 
IBS (n=26), active CD (n=22), active UC (n=20) and HC (n=19) were assessed by means of GC-4 
MS and were found in eight metabolites, displaying gradually increased levels from HC to IBS 5 
to IBD (CD>UC)(18). Unfortunately, no AUC values are given in the article, which complicates 6 
comparison with our study. However, the authors did report considerable overlap of 7 
compound levels between the different subgroups, and a wide dynamic range in all groups 8 
including the controls. 9 
 10 
Volatile organic compounds are considered to reflect (changes in) microbiota composition 11 
and function(8). In a recent study, gut microbiota composition of patients with IBS (n=30) 12 
and IBD (60 UC, 50 CD) were compared to HC (n=50) using DNA sequencing(19). Here, 13 
progressive increase in abundance of species belonging to the phyla Proteobacteria and 14 
Firmicutes were detected from HC to IBS to IBD, whereas Bacteriodetes representation was 15 
gradually reduced along this spectrum. The fact that differences in the microbiota 16 
composition between IBS and HC were shown in this study, whereas we did not find these 17 
differences based on VOC pattern, contradicts the above mentioned hypothesis. However, 18 
not all microbial changes might be reflected in corresponding alterations of VOC 19 
composition. Furthermore, VOC composition is not only influenced by the gut microbiota but 20 
also by systemic metabolic processes and exogenous VOCs like from diet and medication 21 
(20). Despite these facts, our results are in line with the finding that microbial differences 22 
between IBD and HC are larger than IBS and HC.  23 
 24 
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Until now, paediatric studies on faecal VOCs as non-invasive IBD biomarker have focussed on 1 
the discrimination between IBD patients and healthy subjects, lacking a reliable exploration 2 
of the specificity to discriminate IBD from IBS by VOC analysis. Main strength of this study 3 
was that a paediatric IBS/FAP-NOS group was included, allowing for assessment of the 4 
diagnostic accuracy in an intention-to-diagnose design. In addition, potential bias by colonic 5 
lavage, colonoscopy and medication on VOC composition was circumvented in IBD patients, 6 
since we only included de novo treatment-naïve IBD patients. Another strength is the 7 
participation of three medical centres, two referral hospitals and one district hospital. 8 
Furthermore, the performance characteristics of VOC analysis were assessed using 9 
supervised learning models, which are suitable for high-dimensional data as they reduce 10 
dimensionality. These classifiers have previously been shown effective in studies on the 11 
human microbiota(21). We have decided to provide a complete overview of all learning 12 
models applies in this study, as it is not known which model is most useful for VOC analysis.  13 
There were also several limitations. As noted previously, the IBS/FAP-NOS group represents 14 
a heterogeneous population, although no significant differences in VOC profiles were 15 
observed between these two subgroups. We therefore believe that the heterogeneity of this 16 
group has not significantly influenced study outcomes. Another limitation was that we have 17 
not taken potential influence of medication and diet on faecal VOC outcome into account, 18 
which could possibly have influenced the result(22, 23).  Lastly, the potential influence of 19 
sample storage time on metabolic degradation of VOCs has not yet been studied. It could be 20 
hypothesized that storage duration influences VOC outcome by metabolic degradation, even 21 
in frozen state.  Since storage time of the IBD samples differed from that of the HC/IBS/FAP-22 
NOS samples, this may possibly have affected outcome. However, the diagnostic accuracy to 23 
differentiate between IBD and HC is similar to our earlier studies, in which samples with 24 
17 
 
comparable storage duration were used (10). We therefore believe that metabolite 1 
degradation has had no substantial influence on presented results.  2 
 3 
Our findings implicate that faecal VOC analysis may serve as non-invasive biomarker to 4 
discriminate IBS from IBD, with a higher specificity (87%) compared to the currently used 5 
FCP (specificity 68%), but not IBS from healthy state. To discriminate between IBS-like 6 
symptoms and active disease in the course of IBD patients with nonspecific abdominal pain 7 
may be challenging in clinical practice, by limited specificity of FCP. Whether VOC analysis 8 
could serve as an additional biomarker in this specific population needs to be evaluated in 9 
future studies. Combination of the biomarkers FCP and faecal VOCs could possibly lower the 10 
rate of unnecessary colonoscopies in the diagnostic process of IBS/FAP-NOS patients. This 11 
was, however, a proof of principle study to explore the diagnostic value of faecal VOCs in 12 
IBS/FAP-NOS patients. Whether this technique sufficiently contributes to this diagnostic 13 
process needs to be elucidated in a larger ‘intention-to-diagnose’ cohort. 14 
 15 
In conclusion, we have shown that patients with IBD could be distinguished from IBS/FAP-16 
NOS and from HC with a high diagnostic accuracy based on faecal VOC analysis using FAIMS 17 
technology. This signifies its potential role as additional non-invasive biomarker in the 18 
diagnostic work-up of IBD to discriminate from functional gastrointestinal disorders.  19 
 20 
 21 
 22 
  23 
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Table 1. Baseline characteristics  1 
 Crohn’s disease 
(n=15) 
Ulcerative colitis 
(n=15) 
IBS/FAP-NOS 
(n=15 [9/6]) 
Control 
(n=30) 
Sex, male (n [%]) 9 [60] 8 [53] 8 [53] 15 [50] 
Age (median [IQR]), years 
    (minimum-maximum) 
12.8 [5.0] 
(5.9 – 17.9) 
11.8 [7.8] 
(3.2 – 17.8) 
12.9 [8.4] 
(4.4 – 18.1) 
12.7 [8.1] 
(4.1 – 17.9) 
Storage time, median [IQR]), 
months 
    (minimum-maximum) 
31.7 [25.3]¥ 
(8.2 – 54.5) 
45.1 [36.2]¥ 
(15.0 – 59.4) 
0,6 [0.6]¥ 
(0.2 – 2.9) 
1.4 [0.3]¥ 
(0.5 – 4.5) 
BMI (median [IQR]) NA NA 16.7 [5] 17.0 [3] 
Bristol stool chart (n [%]) 
    Type 2 
    Type 3 
    Type 4 
    Type 5 
NA 
 
NA  
2 [14]* 
5 [36] 
4 [29] 
3 [21] 
 
4 [14]* 
19 [66] 
5 [17] 
1 [3] 
Stool frequency (n [%]) 
    2 times a week or less 
    3-6 times a week 
    Once a day 
    2-3 times a day 
    4 times a day or more 
NA 
 
NA  
2 [14]* 
1 [7] 
5 [36] 
5 [36] 
1 [7] 
 
1 [4]* 
9 [33] 
14 [44] 
4 [15] 
1 [4] 
Way of delivery 
    Caesarean section (n [%]) 
    Natural (n [%]) 
NA NA  
3 [23]** 
10 [77] 
 
2 [7]* 
27 [93] 
IBS/FAP 
 
NA NA 33 NA 
Frequency of symptoms 
(IBS/FAP) (n [%]) 
    Once a week 
    2 to 4 times a week 
    Every day 
NA NA  
 
4 [27] 
10 [66] 
1 [7] 
NA 
Duration of symptoms ((n [%]) 
    Over a year 
    2 to 12 months 
    ≤2 months 
 
0 [0]* 
11 [73] 
3 [13] 
 
1 [7] 
7 [47] 
7 [47] 
 
10 [67] 
3 [20] 
2 [13] 
NA 
Physician Global Assessment 
Quiescent 1 0 NA NA 
Mild 0 3 NA NA 
Moderate 5 5 NA NA 
Severe 9 7 NA NA 
Faecal calprotectin (µg/g) 
(median[IQR]) 
1214 [627-1860] 1260 [401-1950] NA NA 
CRP (mg/l) (median[IQR]) 21 [7-68] 4 [<2.5 – 7] NA NA 
Crohn’s disease localisation1 
21 
 
All values were obtained at study inclusion. Localization of IBD was obtained by ileocolonoscopy and 1 
esophagogastroduodenoscopy before treatment initiation, and MR enteroclysis. Abbreviations: IQR, 2 
interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, stricturing; P, penetrating; p, 3 
peri-anal disease. 1Based on Paris classification for inflammatory bowel disease(15).  4 
* Missing data from one subject. ** Missing data from two subjects. ¥ Significant differences between all 5 
subgroups p<0.001, analysed using Wilcoxon-rank-sum tests. 6 
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Ileal (L1) 0 NA NA NA 
Colonic (L2) 6 NA NA NA 
Ileocolonic (L3) 9 NA NA NA 
Proximal disease (L4) 5 NA NA NA 
Crohn’s disease behaviour1 
B1 (NSNP) 11 NA NA NA 
B1p (NSNP+p) 2 NA NA NA 
B2 (S) 0 NA NA NA 
B2p (S + p) 0 NA NA NA 
B3 (P) 0 NA NA NA 
B3p (P + p) 2 NA NA NA 
Ulcerative Colitis1 
Proctitis (E1) NA 3 NA NA 
Left-sided (E2) NA 2 NA NA 
Extensive (E3) NA 10 NA NA 
22 
 
Table 2. Performance characteristics for the discrimination of irritable bowel syndrome, 1 
functional abdominal pain-not otherwise specified, inflammatory bowel disease and 2 
healthy controls by faecal VOC analysis. 3 
 AUC (95% CI) Sensitivity Specificity PPV NPV P 
IBS/FAP-NOS vs IBD 0.94 (0.88 - 1) 1 
 
0.87 0.79 1 0.00000002613 
IBS/FAP-NOS vs CD 0.87 (0.73 – 0.1) 0.93 0.82 0.82 0.92 0.0001617 
IBS/FAP-NOS vs UC 0.96 (0.91 – 1) 1 0.8 0.83 1 0.000007501 
IBS/FAP-NOS vs HC 0.59 (0.41 - 0.77) 0.6 0.63 0.45 0.76 0.1667 
IBS vs FAP-NOS 0.76 (0.44 – 1) 1 0.6 0.83 1 0.9504 
IBD vs HC 0.96 (0.93 – 1) 0.93 0.97 0.97 0.94 0.0000000003982 
UC vs HC 0.98 (0.94 – 1) 0.93 0.97 0.93 0.97 0.0000000005654 
CD vs HC 0.95 (0.88 – 1) 0.93 0.93 0.88 0.97 0.0000001636 
Table 2. Sensitivities, specificities, p-values and AUCs are reported for the respective optimum cut-points.. 4 
Abbreviations: AUC, area under the curve; PPV: positive predictive value; NPV: negative predictive value; IBS: 5 
Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; IBD: Inflammatory 6 
bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HC: Healthy controls. 7 
  8 
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Figure 1. Receiver operating characteristics for irritable bowel syndrome/functional 1 
abdominal pain-not otherwise specified versus inflammatory bowel disease, ulcerative 2 
colitis and Crohn’s disease and IBD versus healthy controls. 3 
4 
Figure 1. AUCs are reported for the Sparse logistic regression analyses. Abbreviations: AUC, area under the curve; 5 
IBS: Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; IBD: Inflammatory 6 
bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HC: Healthy controls. 7 
